Bankrupt DNA testing company 23andMe Holding (OTC:MEHCQ) is set to hold a second auction to sell its assets, including ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company ...

Regeneron Pharmaceuticals (NASDAQ:REGN) shares experienced a significant 19% drop on Friday, May 30, following the unexpected failure of itepekimab, its chronic obstructive pulmonary disease (COPD ...

We recently published a list of These 10 Stocks Just Rocked The Market. In this article, we are going to take a look at where ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron will make an upfront payment to Hansoh ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced on Monday that its experimental drug, when combined with Novo Nordisk ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...